FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| 1.16 | |
| 1.25 | |
| - | |
| 1.32 | |
| 1.055 | |
| 0.3333-2.93 | |
| 122 M | |
| 99 475 K | |
| 167 M | |
| -0.33 | |
| 0.713 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Insight into Fournier's Q4 Moves: DISH Network Exit and EchoStar Corp Addition Alan Fournier (Trades, Portfolio), the seasoned investor behind the transformation of his firm into a family office, has...
Key Insights Institutions' substantial holdings in FibroGen implies that they have significant influence over the company's share price 50% of the business is held by the top 7 shareholders Using dat...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
